The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Spectrum Pharmaceuticals Inc. under investigation for potential securities fraud

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

SPECTRUM PHARMACEUTICALS INC. is under investigation by national securities law firm Faruqi & Faruqi LLP for potential securities fraud. The firm said it’s investigating whether the company and its executives violated federal securities laws by issuing materially misleading information about the company. Specifically, on Sept. 14, the FDA Oncologic Drugs Advisory Committee (ODAC) voted against...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
By Claire Marie Porter, Paul Goldberg and Jacquelyn Cobb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account